Skip to main content
. 2025 Dec 19;18(1):5. doi: 10.3390/cancers18010005
ADA Anti-Drug Antibody
ADC Antibody-Drug Conjugate
AST Aspartate Aminotransferase
BCMA B-Cell Maturation Antigen
BSA Body Surface Area
CM Compartment Model
CL Clearance
CrCL Creatinine Clearance
DAR Drug-to-Antibody Ratio
ECD Extracellular Domain
ECOG Eastern Cooperative Oncology Group
F Bioavailability
FcRn Neonatal Fc Receptor
FDA Food and Drug Administration
mAb Monoclonal Antibody
MMAE Monomethyl Auristatin E
MMAF Monomethyl Auristatin F
PBPK Physiologically Based Pharmacokinetics
PD Pharmacodynamics
PK Pharmacokinetics
PopPK Population Pharmacokinetics
SC Subcutaneous
TAb Total Antibody
tADC Total Antibody-Drug Conjugate
TDCL Time-Dependent Clearance
T-DM1 Trastuzumab Emtansine
T-Dxd Trastuzumab Deruxtecan
TMDD Target-Mediated Drug Disposition
T-vc-MMAE Trastuzumab-MMAE
Vss Volume of Distribution